New epilepsy drug shows promise in long-term safety trial for rare brain conditions
NCT ID NCT05626634
First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This study looked at the long-term safety of a drug called LP352 in people aged 12 to 65 with severe epilepsy and developmental problems, including Dravet and Lennox-Gastaut syndromes. All 41 participants had already completed an earlier study and continued treatment for up to 52 weeks. The main goal was to check for side effects and see if the drug helped reduce seizures over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32803, United States
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Austin Epilepsy Care Center
Austin, Texas, 78758, United States
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Boston Children's Health Physicians LLP
Hawthorne, New York, 10532, United States
-
Child Neurology Consultants of Austin
Austin, Texas, 78757, United States
-
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland, 20817, United States
-
Northeast Regional Epilepsy Group
Staten Island, New York, 10305, United States
-
Northwell Health
New York, New York, 10075, United States
-
Northwest Florida Clinical Research Group
Gulf Breeze, Florida, 32561, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
OnSite Clinical Solutions LLC
Charlotte, North Carolina, 98277, United States
-
Providence Neurological Specialties-East
Portland, Oregon, 97213, United States
-
Queensland Children's Hospital
South Brisbane, Queensland, 4101, Australia
-
Rancho Los Amigos National Rehabilitation Center (RLANRC)
Downey, California, 90242, United States
-
Research Institute of Orlando
Orlando, Florida, 32806, United States
-
Spectrum Health
Grand Rapids, Michigan, 49503, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of South Florida
Tampa, Florida, 33606, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
University of Washington Valley Medical Center
Renton, Washington, 98055, United States
-
Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27157, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.